StockNews.com Downgrades iCAD (NASDAQ:ICAD) to Sell

iCAD (NASDAQ:ICAD) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

iCAD Price Performance

ICAD opened at $2.47 on Tuesday. The company has a market cap of $65.55 million, a price-to-earnings ratio of -19.00 and a beta of 1.95. The firm has a 50 day simple moving average of $2.64 and a 200 day simple moving average of $2.05. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $3.78.

iCAD (NASDAQ:ICAD) last posted its quarterly earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. waypoint wealth counsel increased its position in shares of iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after acquiring an additional 4,400 shares in the last quarter. Summit Trail Advisors LLC acquired a new stake in shares of iCAD during the 4th quarter worth about $214,000. Thompson Davis & CO. Inc. acquired a new stake in shares of iCAD during the 4th quarter worth about $31,000. First Eagle Investment Management LLC lifted its stake in shares of iCAD by 6.1% during the 4th quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock worth $1,311,000 after buying an additional 41,000 shares during the last quarter. Finally, PKS Advisory Services LLC acquired a new stake in shares of iCAD during the 4th quarter worth about $53,000. Institutional investors and hedge funds own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.